Read Simon 4
4 · Ra Pharmaceuticals, Inc. · Filed Sep 16, 2019
Insider Transaction Report
Form 4
Read Simon
Chief Scientific Officer
Transactions
- Exercise/Conversion
COMMON STOCK
2019-09-12$2.87/sh+10,000$28,700→ 16,234 total - Sale
COMMON STOCK
2019-09-12$25.41/sh−10,000$254,050→ 6,234 total - Exercise/Conversion
Stock Options (Right to buy)
2019-09-12−10,000→ 76,142 totalExercise: $2.87Exp: 2026-06-16→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.09 to $26.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter.